S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
The Most Bought AI Stock by Congress Isn’t NVIDIA
5 Dividend Kings Stocks to Load Up on Now
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
NASDAQ:GANX

Gain Therapeutics (GANX) Stock Price, News & Analysis

$3.73
-0.07 (-1.84%)
(As of 03/27/2024 ET)
Today's Range
$3.60
$3.90
50-Day Range
$3.27
$5.04
52-Week Range
$2.00
$6.19
Volume
114,019 shs
Average Volume
173,922 shs
Market Capitalization
$48.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.33

Gain Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
123.4% Upside
$8.33 Price Target
Short Interest
Healthy
0.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Gain Therapeutics in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.55) to ($1.18) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.91 out of 5 stars

Medical Sector

576th out of 939 stocks

Pharmaceutical Preparations Industry

267th out of 422 stocks

GANX stock logo

About Gain Therapeutics Stock (NASDAQ:GANX)

Gain Therapeutics, Inc., a biotechnology company, researches and develops novel therapies to treat diseases caused by protein misfolding in Switzerland and Spain. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. Its lead product candidate includes GT-02287, for the treatment of GBA1 Parkinson's disease. In addition, the company is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.

GANX Stock Price History

GANX Stock News Headlines

Crypto Market Preps For Trillions Worth of Inflows!
Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.
Gain Therapeutics (NASDAQ:GANX) Shares Down 10.1%
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
GANX Mar 2024 7.500 call
Amgen 4Q Revenue Surges as Acquisition Boosts Results
GANX Gain Therapeutics, Inc.
See More Headlines
Receive GANX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gain Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/28/2024
Next Earnings (Estimated)
5/10/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:GANX
Fax
N/A
Employees
28
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.33
High Stock Price Target
$10.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+123.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-17,590,000.00
Pretax Margin
-40,138.18%

Debt

Sales & Book Value

Annual Sales
$140,000.00
Book Value
$1.59 per share

Miscellaneous

Free Float
11,490,000
Market Cap
$48.15 million
Optionable
Optionable
Beta
0.47
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

GANX Stock Analysis - Frequently Asked Questions

Should I buy or sell Gain Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gain Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GANX shares.
View GANX analyst ratings
or view top-rated stocks.

What is Gain Therapeutics' stock price target for 2024?

3 equities research analysts have issued 1 year price objectives for Gain Therapeutics' stock. Their GANX share price targets range from $6.00 to $10.00. On average, they expect the company's share price to reach $8.33 in the next twelve months. This suggests a possible upside of 123.4% from the stock's current price.
View analysts price targets for GANX
or view top-rated stocks among Wall Street analysts.

How have GANX shares performed in 2024?

Gain Therapeutics' stock was trading at $3.27 on January 1st, 2024. Since then, GANX stock has increased by 14.1% and is now trading at $3.73.
View the best growth stocks for 2024 here
.

Are investors shorting Gain Therapeutics?

Gain Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 156,700 shares, an increase of 16.4% from the February 29th total of 134,600 shares. Based on an average daily volume of 171,900 shares, the short-interest ratio is presently 0.9 days. Currently, 0.9% of the company's shares are short sold.
View Gain Therapeutics' Short Interest
.

When is Gain Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our GANX earnings forecast
.

How were Gain Therapeutics' earnings last quarter?

Gain Therapeutics, Inc. (NASDAQ:GANX) announced its quarterly earnings data on Friday, November, 12th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.36) by $0.03. The company earned $0.03 million during the quarter, compared to analyst estimates of $0.04 million.

When did Gain Therapeutics IPO?

Gain Therapeutics (GANX) raised $40 million in an initial public offering (IPO) on Thursday, March 18th 2021. The company issued 3,600,000 shares at $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

Who are Gain Therapeutics' major shareholders?

Gain Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Royal Bank of Canada (1.55%), Vanguard Group Inc. (0.68%), Vanguard Group Inc. (0.68%), Northern Trust Corp (0.34%), Raymond James & Associates (0.18%) and Citadel Advisors LLC (0.00%). Insiders that own company stock include Eric I Richman and Matthias Alder.
View institutional ownership trends
.

How do I buy shares of Gain Therapeutics?

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:GANX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners